OCULAR THERAPEUTIX, INC Employee Count
The employee counts OCULAR THERAPEUTIX, INC states in its annual reports on SEC EDGAR, each as filed.
- 2025-12-31: Employees (as filed) 325; Filing 2026-02-05; Lease expense per employee $11,698.46.
- 2024-12-31: Employees (as filed) 274; Filing 2025-03-03; Lease expense per employee $14,583.94.
- 2023-12-31: Employees (as filed) 267; Filing 2024-03-11; Lease expense per employee $13,670.41.
- 2022-12-31: Employees (as filed) 274; Filing 2023-03-06; Lease expense per employee $11,405.11.
- Available history
- 2016-12-31 to 2025-12-31
Historical Employee Count
| Date | Employees (as filed) | Filing | Lease expense per employee |
|---|---|---|---|
| 2025-12-31 | 325 full-time | 2026-02-05 | $11,698.46 total lease cost |
| 2024-12-31 | 274 full-time | 2025-03-03 | $14,583.94 total lease cost |
| 2023-12-31 | 267 full-time | 2024-03-11 | $13,670.41 total lease cost |
| 2022-12-31 | 274 full-time | 2023-03-06 | $11,405.11 total lease cost |
| 2021-12-31 | 228 full-time | 2022-02-28 | $13,644.74 total lease cost |
| 2020-12-31 | 181 full-time | 2021-03-11 | $17,099.45 total lease cost |
| 2019-12-31 | 161 full-time | 2020-03-12 | $16,198.76 total lease cost |
| 2018-12-31 | 167 full-time | 2019-03-07 | $10,706.59 lease and rental expense |
| 2017-12-31 | 119 full-time | 2018-03-08 | $14,563.03 lease and rental expense |
| 2016-12-31 | 118 full-time | 2017-03-10 | $9,186.44 lease and rental expense |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |